Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New findings from Pennsylvania State University in the area of breast cancer published
July 10th, 2008
" To determine the effect of elevated serum TIMP-1 on the response of patients with metastatic breast cancer to an aromatase inhibitor versus tamoxifen. Patients and Methods Five hundred twenty-two patients estrogen receptor - positive metastatic breast cancer were randomly assigned to receive first-line hormone therapy with letrozole or tamoxifen," investigators in the United States report. "Serum tissue inhibitor of metalloproteinases-1 ( TIMP-1) levels were measured using an enzyme-linked immunosorbent assay. Pretreatment serum TIMP-1 was elevated in 120 (23%) of 522 patients. Patients with elevated serum TIMP-1 had a significantly reduced objective response rate...
Source: Women's Health Weekly (2008-07-10)
|
